NCT03830125View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

November 24, 2019

Study Completion Date

November 24, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

BBT-877, Single dose

Single dose of BBT-877, 5 dose levels, oral capsule

DRUG

Placebo group

Placebo matched to BBT-877, oral capsule

DRUG

BBT-877, Multiple doses

Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Collaborators (1)

KCRN Research, LLC
All Listed Sponsors
collaborator

KCRN Research, LLC

INDUSTRY

lead

Bridge Biotherapeutics, Inc.

INDUSTRY

NCT03830125 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects | Biotech Hunter | Biotech Hunter